Not proposed during and a pair of months after itraconazole. If coadministration with fentanyl is critical, carefully watch for respiratory depression and sedation and consider fentanyl dose changes until stable drug effects are attained.
iloprost, fentanyl. Both boosts effects on the other by pharmacodynamic synergism. Modify Therapy/Observe Closely. When administering iloprost IV, consider momentary discontinuation of concomitant vasodilators or other medications that lower blood pressure to mitigate potential additive hypotensive effects.
bremelanotide will reduce the level or effect of fentanyl by Other (see comment). Prevent or Use Alternate Drug. Bremelanotide may possibly slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications.
olanzapine/samidorphan decreases effects of fentanyl by pharmacodynamic antagonism. Contraindicated. Samidorphan elicits opioid antagonistic effects and raises risk of precipitating acute opioid withdrawal in patients dependent on opioids.
Opioids can cause sleep-related respiration disorders together with central sleep apnea (CSA) and snooze-related hypoxemia; opioid use increases risk of CSA inside a dose-dependent trend; in patients who existing with CSA, consider lowering opioid dosage using best tactics for opioid taper
You can find risks on the mother and infant connected with use for an prolonged period of time during pregnancy
fentanyl, dexchlorpheniramine. Both will increase toxicity of the other by pharmacodynamic synergism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with anticholinergics could maximize risk for fentanyl actavis urinary retention and/or intense constipation, which may bring on paralytic ileus.
Watch Closely (two)fentanyl will boost the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
fentanyl intranasal and fentanyl each raise sedation. Steer clear of or Use Alternate Drug. Restrict use to patients for whom substitute treatment options are inadequate
Givinostat is usually a weak CYP3A4 inhibitor. Intently keep an eye on if coadministered with orally administered CYP3A4 sensitive substrates for which a little change in substrate plasma concentration could lead to really serious toxicities.
C: Use with warning if Added benefits outweigh risks. Animal scientific tests show risk and human scientific tests not out there or neither animal nor human research carried out.
If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at Recurrent intervals and consider fentanyl dose adjustments right until stable drug effects are obtained.
diazepam buccal and fentanyl both of those raise sedation. Avoid or Use Alternate Drug. Restrict use to patients for whom choice treatment options are inadequate
If this comes about, take the tablet from your mouth straight absent. Rinse your mouth with drinking water and spit any remaining parts in the tablet into a sink or rest room.